Ban on Fixed Dose Combination (FDC) Drugs
The character of science is fundamentally open to new evidence and emerging facts, emphasizing the need for agility in updating guidelines. Recently, the Health Ministry imposed a ban on 16 FDC drugs, citing lack of therapeutic justification and potential risks.
Key Reasons for the Ban
- The combinations are deemed irrational or unsafe.
- Potential risks to patients include ineffectiveness and harmful reactions.
Understanding FDCs
- An FDC comprises two or more active pharmacological ingredients in a single dosage.
- Originally designed to improve treatment compliance, especially in chronic conditions like Tuberculosis, by reducing the pill burden and sometimes enhancing therapeutic effectiveness.
- Issues with FDCs include:
- Inability to adjust individual doses.
- Potential for allergic reactions without identifying specific causative ingredients.
- Exposure to unnecessary side effects due to nonessential drugs in the combination.
Implications of the Ban
- Regulatory Enforcement: State Drug Controllers and other regulatory bodies must enforce the ban.
- Instructions for halting the stock and sale of banned FDCs must be sent to all manufacturers, importers, distributors, and pharmacies.
Historical Context
- In March 2016, over 330 FDCs were banned for being irrational.
- 19% of those banned were antibiotics, linked to growing antimicrobial resistance.
Challenges and the Path Forward
- Past instances showed continued sales of banned drugs due to ineffective communication.
- The government must enhance monitoring and supervision to ensure the ban's benefits reach all levels.
